Survival status, efficacy and safety of combination chemotherapies in previously untreated patients with follicular lymphoma
10.3760/cma.j.issn.1009-9921.2013.11.003
- VernacularTitle:联合化疗方案治疗初治滤泡性淋巴瘤患者的生存、疗效及安全性
- Author:
Wei ZHANG
;
Wei WAN
;
Jing WANG
;
Wenli WAN
;
Jijun WANG
;
Kai HU
;
Xiaoyan KE
- Publication Type:Journal Article
- Keywords:
Lymphoma,follicular;
Antineoplastic combined chemotherapy protocols;
Treatment outcome
- From:
Journal of Leukemia & Lymphoma
2013;22(11):650-654,657
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the survival status and efficacy,prognosis and safety of several combined chemotherapies in previously untreated patients with follicular lymphoma (FL).Methods Clinical data of 62 previously untreated FL patients were analyzed retrospectively,in order to analyse survival status and to compare the efficacy and safety of different combined chemotherapies.Results The percent of FL patients achieved complete response (CR) after initial therapy was 80.0 ％ (44/55),while achieved for more than 5 years accounted for 23.6 ％ (13/55).Ten-year overall survival (OS) rate was 77.8 ％.The relapse rate was 34.5 ％,and the OS rate in patients with recurrence was significantly lower than in non-recurrence patients (93.8 ％ vs 61.6 ％,P =0.012).The disease-free survival (DFS) and progression-free survival (PFS)rates in FC/FMD (fludarabine,cyclophosphamide/fludarabine,mitoxantrone,dexamethasone) group comparing with CHOP (cyclophosphamide,epirubicin,vincristine,prednisone)-like group were significantly higher (80.0 ％ vs 21.1％ and 80.0 ％ vs 29.2 ％,P ＜ 0.05),but the differences had no statistical significance when adding rituximab (88.9 ％ vs 72.7 ％ and 90.0 ％ vs 73.5 ％,P ＞ 0.05).The OS,DFS and PFS rates in rituximab group were higher than those in the group without it (96.4 ％,79.2 ％ and 79.2 ％ vs 82.9 ％,39.3 ％ and 44.5 ％,P ＜ 0.05).The DFS and PFS rates in fludarabine group comparing with the group without it were significantly higher (86.2 ％ vs 49.4 ％,87.1％ vs 52.7 ％,P ＜ 0.05),but the differences between OS rates had no statistical significance (92.9 ％ vs 89.1％,P ＞ 0.05).The major adverse effects were hematologic toxicity,infection,nausea/vomiting and abnormal liver function.The hematologic toxicity of chemotherapies including fludarabine was stronger,but well-tolerated.Conclusion With initial combined chemotherapies,the CR rate of FL could receive a higher level.It is considered that chemotherapy might cure a part of FL patients thoroughly.Rituximab could increase the OS time significantly.FC/FMD regimen could increase the PFS time,comparing with CHOP-like regimen,while the difference has no statistical significance when adding rituximab.Systemic chemotherapies are well tolerated.
